GlobeNewswire

The FNC receives important sustainability and quality awards from the coffee industry

Dela

Rainforest Alliance, the Coffee Quality Institute (CQI) and the Specialty Coffee Association (SCA) have honored Colombian coffee growers

BOGOTÁ, Colombia, May 15, 2018 (GLOBE NEWSWIRE) -- In recent weeks, the Colombian Coffee Growers Federation (FNC) has received important sustainability and quality awards from key players in the global coffee industry such as Rainforest Alliance, the Coffee Quality Institute (CQI), and the Specialty Coffee Association (SCA).

Last week, on May 9, the FNC received one of the Rainforest Alliance Sustainable Standard-Setters Awards for its exceptional commitment to sustainability, improving coffee farmers' livelihoods, and conserving forests.

Since its creation in 1927, the FNC has worked to improve quality of life of the over 540,000 coffee-growing families it represents nowadays. "For Colombian coffee farmers, sustainability is closely linked to their raison d'être. So much so that over 236,000 coffee farms in Colombia meet some sustainability standard, and by 2027, when the FNC becomes 100 years old, we aspire to make all Colombian coffee sustainable," said the FNC CEO, Roberto Vélez, upon receiving the recognition on behalf of the Colombian coffee growers.

"The individuals, communities, and businesses we have highlighted are working to address the significant and related challenges of climate change, rural poverty, and biodiversity loss. Their work has resulted in real changes on the ground, and is helping to improve conditions for farmers and forest communities," said Han de Groot, the Rainforest Alliance CEO.

CQI 2018 Leadership Medal of Merit

On April 21 in Seattle, during its annual luncheon, the Coffee Quality Institute (CQI) awarded its 2018 Leadership Medal of Merit, in the corporate category, to the FNC, honoring its commitment of over 90 years to improving farmers' livelihoods, fostering sustainability, and increasing coffee quality, helping to strengthen the Colombian coffee sector as a whole.

"Thanks in large part to the work of the FNC, quality and sustainability are not recent trends for Colombian coffee growers," said CQI Executive Director, David Roche. "These have been a priority for over 90 years, along with differentiating quality, adding value, and staying ahead of the curve on economic, social and environmental practices."

"We receive this recognition with double gratitude: firstly, for the prestige of CQI in the global coffee industry, and secondly, because it comes at a crucial time, when we redouble efforts to increase sustainability of coffee farmers not only in Colombia, but in the world, with an approach of shared responsibility of all actors in the chain," said Vélez, the FNC CEO, on behalf of all Colombian producers.

The CQI recognized that the FNC has undertaken important initiatives and taken visionary measures to strengthen the Colombian coffee sector. The FNC's programs also help farmers prepare for challenges ahead, including adapting to climate change, fostering sustainable coffee farming, and stimulating generational continuity, the CQI highlighted.

Manos al Agua is granted SCA Sustainability Award

On April 19, also in Seattle, the Manos al Agua Project, implemented by the FNC as part of a public-private partnership, was granted the Specialty Coffee Association (SCA) Sustainability Award 2018, the most important of its kind, thanks to the results achieved in the category of Sustainable Projects.

The award was achieved thanks to the importance and results of Manos al Agua (including installation of on-farm water saving and treatment systems), as an innovative project for integrated water resources management in coffee river basins, a replicable model for sustainable rural development in Colombia.

The SCA Sustainability Award is granted since 2004 to companies and organizations that create and implement innovative projects or business models to expand and promote coffee sustainability in the world, while inspiring others to start similar initiatives.

"Manos al Agua is a holistic project, one of the most successful of the Colombian coffee institutions," Vélez, the FNC CEO, noted.

A 5-year public-private partnership, the Project started in 2013 and is made up of the FNC, the Dutch Cooperation Agency, the private companies Nestlé & Nespresso; the Colombian Coffee Research Center (Cenicafé) and the Wageningen University as scientific-academic partners, and Colombia's Presidential Agency of International Cooperation (APC-Colombia).

Contact Information:
FNC Press Office
(57+1) 3136600 Ext. 1790
martha.sanchez@cafedecolombia.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Federacion Nacional de Cafeteros de Colombia-Fondo Nacional del Café via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum